Drug discovery is saturated: ~86% of GWAS participants are of European ancestry, yet Asia is 60% of humanity where there are still plenty of genetic variants to explore. Varios consolidates the largest Asian iPSC biobank — deep-phenotyped donors across Southeast Asian ancestries — into a multi-omic discovery engine for pharma, biotech, and AI.
Population-scale cells, multi-modal data, disease-relevant phenotypes, ground-truth tissues — converging on a discovery pipeline that learns from each new donor.
1000+ Asian iPSC lines to power both discovery and validation — scalable on demand. A living, genetically diverse human substrate, produced at a fraction of industry cost.
Cellular function, cellular and clinical -omics, EHR, and imaging — layered on the same donors. The density that drives novel insights and de-risks decisions.
Patient-derived iPSC disease models with phenotyping calibrated to serve as proxies for clinical endpoints — so validation happens in human biology, not in species that don’t translate.
Healthy and diseased human tissues — the ground-truth reference that anchors every cellular and computational readout back to real patients.
Where the platform culminates. The same iPSCs that power discovery also support patient stratification, toxicity prediction, and pharmacogenomics — end-to-end human context from target to trial.
A closed-loop engine that links population-scale genetics to patient-derived cells — and patient-derived cells back to real clinical phenotypes.
We identify indications and clinical endpoints that associate well with cellular phenotypes. We combine multi-ancestry GWAS, clinical cohorts, and cellular data for genetically-supported, actionable targets that have the best chance of affecting endpoints.
Our iPSC library recapitulates clinical phenotypes — molecular markers, cellular dysfunction, drug response — so we validate targets where it matters.
Integrated ML on genotype × phenotype × cellular response predicts who benefits, informing smaller, faster, more precise clinical studies.
We work with pharma, biotech, AI platforms, and academic consortia on target validation, data licensing, and co-development.
A focused, platform-enabled portfolio. Assets are selected for genetic support, tractability, and unmet need — then progressed through Varios’ in-house iPSC pharmacology platform.
A cardio-inflammation and cardiometabolic franchise built from population-scale human biology. Program-level details available under CDA.
Disc. = discovery · Lead Opt. = lead optimisation · IND-en. = IND-enabling studies. Partner program details available under CDA.
Peer-reviewed work from the Varios team and extended network — spanning iPSC disease modelling, cardiovascular genetics, and immuno-cardiology.
Citations above are representative selections from the team's peer-reviewed output; full publication lists available via Google Scholar / ORCID on request.